# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.
Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 51.06 ...
Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Addition...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as...
Key Findings from the Phase 3 GBS Trial of ANX005 30 mg/kg Treatment Phase 3 trial informed by dose-ranging Phase 1b trial, ...